上海莱士：接受银河证券、博时基金调研

Group 1 - The company Shanghai Laishi (SZ 002252) announced a research meeting scheduled for August 7, 2025, from 10:00 to 11:00, where the Deputy General Manager and Board Secretary Liu Zheng will participate and answer investor questions [2] - For the year 2024, the revenue composition of Shanghai Laishi is as follows: blood products production and sales account for 98.48%, testing equipment and reagents account for 1.48%, and other businesses account for 0.03% [2]